Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Tandem Diabetes Care (TNDM) EBITDA Margin (2016 - 2025)

Tandem Diabetes Care's EBITDA Margin history spans 13 years, with the latest figure at 0.06% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 173.0% year-over-year to 0.06%; the TTM value through Dec 2025 reached 19.43%, down 886.0%, while the annual FY2025 figure was 19.43%, 886.0% down from the prior year.
  • EBITDA Margin reached 0.06% in Q4 2025 per TNDM's latest filing, up from 7.92% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 4.85% in Q4 2021 to a low of 72.11% in Q1 2023.
  • Average EBITDA Margin over 5 years is 14.68%, with a median of 8.94% recorded in 2022.
  • Peak YoY movement for EBITDA Margin: plummeted -6236bps in 2023, then surged 4863bps in 2024.
  • A 5-year view of EBITDA Margin shows it stood at 4.85% in 2021, then tumbled by -218bps to 5.72% in 2022, then tumbled by -135bps to 13.43% in 2023, then surged by 87bps to 1.79% in 2024, then skyrocketed by 97bps to 0.06% in 2025.
  • Per Business Quant, the three most recent readings for TNDM's EBITDA Margin are 0.06% (Q4 2025), 7.92% (Q3 2025), and 20.25% (Q2 2025).